These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
670 related articles for article (PubMed ID: 21615192)
1. Phaeochromocytoma: a catecholamine and oxidative stress disorder. Pacak K Endocr Regul; 2011 Apr; 45(2):65-90. PubMed ID: 21615192 [TBL] [Abstract][Full Text] [Related]
2. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Eisenhofer G; Lenders JW; Timmers H; Mannelli M; Grebe SK; Hofbauer LC; Bornstein SR; Tiebel O; Adams K; Bratslavsky G; Linehan WM; Pacak K Clin Chem; 2011 Mar; 57(3):411-20. PubMed ID: 21262951 [TBL] [Abstract][Full Text] [Related]
3. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002 [TBL] [Abstract][Full Text] [Related]
4. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. Eisenhofer G; Timmers HJ; Lenders JW; Bornstein SR; Tiebel O; Mannelli M; King KS; Vocke CD; Linehan WM; Bratslavsky G; Pacak K J Clin Endocrinol Metab; 2011 Feb; 96(2):375-84. PubMed ID: 21147885 [TBL] [Abstract][Full Text] [Related]
5. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874 [TBL] [Abstract][Full Text] [Related]
6. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters. van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126 [TBL] [Abstract][Full Text] [Related]
7. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. Eisenhofer G; Lenders JW; Linehan WM; Walther MM; Goldstein DS; Keiser HR N Engl J Med; 1999 Jun; 340(24):1872-9. PubMed ID: 10369850 [TBL] [Abstract][Full Text] [Related]
8. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846 [TBL] [Abstract][Full Text] [Related]
10. Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1. Butz JJ; Yan Q; McKenzie TJ; Weingarten TN; Cavalcante AN; Bancos I; Young WF; Schroeder DR; Martin DP; Sprung J Surgery; 2017 Dec; 162(6):1259-1269. PubMed ID: 28919049 [TBL] [Abstract][Full Text] [Related]
11. PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS. Gupta G; Pacak K; Endocr Pract; 2017 Jun; 23(6):690-704. PubMed ID: 28332883 [TBL] [Abstract][Full Text] [Related]
15. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588 [TBL] [Abstract][Full Text] [Related]
16. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. Elder EE; Elder G; Larsson C J Surg Oncol; 2005 Mar; 89(3):193-201. PubMed ID: 15719371 [TBL] [Abstract][Full Text] [Related]
17. Pheochromocytoma as a catecholamine producing tumor: implications for clinical practice. Zelinka T; Eisenhofer G; Pacak K Stress; 2007 Jun; 10(2):195-203. PubMed ID: 17514588 [TBL] [Abstract][Full Text] [Related]
18. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. Timmers HJ; Kozupa A; Eisenhofer G; Raygada M; Adams KT; Solis D; Lenders JW; Pacak K J Clin Endocrinol Metab; 2007 Mar; 92(3):779-86. PubMed ID: 17200167 [TBL] [Abstract][Full Text] [Related]
19. PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE. Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820 [TBL] [Abstract][Full Text] [Related]
20. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. Eisenhofer G; Walther MM; Huynh TT; Li ST; Bornstein SR; Vortmeyer A; Mannelli M; Goldstein DS; Linehan WM; Lenders JW; Pacak K J Clin Endocrinol Metab; 2001 May; 86(5):1999-2008. PubMed ID: 11344198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]